Patents by Inventor Laurence E. Burgess

Laurence E. Burgess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6680336
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: January 20, 2004
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Preparation of phosphatase inhibitors
    Patent number: 6586467
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: July 1, 2003
    Assignee: Array BioPharma Inc.
    Inventors: Laurence E. Burgess, John J. Gaudino, Robert D. Groneberg, Mark H. Norman, Martha E. Rodriguez, Xicheng Sun, Eli M. Wallace
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20020169196
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: February 15, 2002
    Publication date: November 14, 2002
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Materials and methods to potentiate cancer treatment
    Publication number: 20020165218
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Application
    Filed: August 28, 2001
    Publication date: November 7, 2002
    Inventors: James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6458787
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: October 1, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlacter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6423710
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: July 23, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6376489
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory disease and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: April 23, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Preparation of phosphatase inhibitors
    Publication number: 20020040003
    Abstract: Disclosed are compounds of the Formula I 1
    Type: Application
    Filed: July 5, 2001
    Publication date: April 4, 2002
    Inventors: Laurence E. Burgess, John J. Gaudino, Robert D. Groneberg, Mark H. Norman, Martha E. Rodriguez, Xicheng Sun, Eli M. Wallace
  • Compounds which inhibit tryptase activity
    Patent number: 6362216
    Abstract: The present invention is directed to compounds which are capable of inhibiting the activity of tryptase. Such compounds are useful in the treatment or prevention of inflammatory disease, particularly those disease states which are mediated by mast cell activation. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds and methods for treating or preventing an inflammatory disease.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: March 26, 2002
    Assignee: Array Biopharma Inc.
    Inventors: Laurence E. Burgess, James P. Rizzi
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6258833
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: July 10, 2001
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlacter
  • Sulfonamide bridging compounds that inhibit tryptase activity
    Patent number: 6221914
    Abstract: The present invention is directed to compounds which are capable of inhibiting the activity of tryptase. Such compounds are useful in the treatment or prevention of inflammatory disease, particularly those disease states which are mediated by mast cell activation. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds and methods for treating or preventing an inflammatory disease.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: April 24, 2001
    Assignee: Array Biopharma Inc.
    Inventors: Laurence E. Burgess, James P. Rizzi
  • Cyclic sulfone derivatives
    Patent number: 5883131
    Abstract: A compound of the formula ##STR1## wherein n, p, q, X, Y, Z and Ar are as defined herein, useful in the treatment of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis or other diseases characterized by matrix metalloprotenase activity, as well as AIDS, sepsis, septic shock or other diseases involving the production of TNF.
    Type: Grant
    Filed: July 9, 1997
    Date of Patent: March 16, 1999
    Assignee: Pfizer Inc.
    Inventors: Laurence E. Burgess, James P. Rizzi, David J. Rawson
  • Regioselective synthesis of 4-chloro-2-thiophenecarboxylic acid
    Patent number: 5648502
    Abstract: 4-Chloro-2-thiophenecarboxylic acid is made by forming a compound of formula (Ia), disclosed herein, wherein R.sup.3 is (C.sub.1 -C.sub.6) alkyl, phenyl, or benzyl; converting the compound to a compound of formula (IVa), disclosed herein, and removing the silyl group R.sub.3 Si--. The product is useful as an intermediate in making pharmaceutical products.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: July 15, 1997
    Assignee: Pfizer Inc.
    Inventors: Laurence E. Burgess, Gary R. Schulte